Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Phase 1/2 Recruiting
36 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/2 Recruiting
442 enrolled
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Phase 1/2 Recruiting
280 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
iMATRIX GLO
Phase 1/2 Recruiting
65 enrolled
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Phase 1/2 Recruiting
98 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Phase 1/2 Recruiting
366 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
MK-6070-003
Phase 1/2 Recruiting
170 enrolled
KEYNOTE-365
Phase 1/2 Recruiting
1,200 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Phase 1/2 Recruiting
123 enrolled
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1/2 Recruiting
40 enrolled
Acclaim-1
Phase 1/2 Recruiting
158 enrolled
ESMART
Phase 1/2 Recruiting
472 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Phase 1/2 Recruiting
60 enrolled
RAGE
Phase 1/2 Recruiting
48 enrolled
SOLARA
Phase 1/2 Recruiting
41 enrolled
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2 Recruiting
248 enrolled
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
444 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Phase 1/2 Recruiting
300 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/2 Recruiting
150 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Phase 1/2 Recruiting
52 enrolled
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2 Recruiting
320 enrolled
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/2 Recruiting
100 enrolled
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Phase 1/2 Recruiting
86 enrolled
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Phase 1/2 Recruiting
350 enrolled
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2 Recruiting
100 enrolled
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Phase 1/2 Recruiting
18 enrolled
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/2 Recruiting
120 enrolled
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2 Recruiting
400 enrolled
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phase 1/2 Recruiting
40 enrolled
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
282 enrolled
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Phase 1/2 Recruiting
25 enrolled
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Phase 1/2 Recruiting
90 enrolled